{
    "clinical_study": {
        "@rank": "110811", 
        "arm_group": {
            "arm_group_label": "Histological biopsy procedures", 
            "description": "Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis"
        }, 
        "biospec_descr": {
            "textblock": "Biopsies are taken from the enrolled patients and these biopsies are send to the pathology\n      department for histopathological analysis."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Investigation of application possibilities of optical spectroscopy within the field of\n      oncology. Optical spectroscopy enables the possibility to specifically differentiate between\n      different (human) tissues. The hypothesis is that incorporation of this technique into\n      existing medical devices (e.g. biopsy needle) would enlarge the accuracy and reliability of\n      these devices. The purpose is to improve and speed up the diagnostics and therapy of the\n      malignancies."
        }, 
        "brief_title": "Optical Detection of Malignancy During Percutaneous Interventions", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pulmonary Coin Lesion", 
            "Colon Cancer Liver Metastasis", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Colonic Neoplasms", 
                "Solitary Pulmonary Nodule", 
                "Neoplasm Metastasis", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Objective:\n\n      In this observational study the investigators aim to evaluate whether optical spectroscopy\n      can correctly diagnose malignant tissue in the existing clinical workflow of percutaneous\n      interventions in lung, liver, and breast.\n\n      Secondary Objective:\n\n      During the measurement procedure, possible improvements of the measurement hardware will be\n      recorded. Analysis of this documentation will provide information for possible alterations\n      of hardware design for improved clinical applicability in the future. Special attention will\n      be paid to observe how the procedure fits in the standard workflow of the radiologist."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a suspicious lesion in lung or liver who are scheduled for a standard\n             core biopsy procedure\n\n          -  Patient planned for percutaneous RFA of colorectal liver metastasis\n\n          -  Written informed consent\n\n          -  Patients \u2265 18 years old\n\n          -  Breast patients with a BIRADS score 4 or 5\n\n        General Exclusion criteria:\n\n          -  Patients who have higher risk of bleeding\n\n          -  Patients with suspected sensitivity to light; e.g. patients who have had photodynamic\n             therapy\n\n        Breast Specific Exclusion criteria:\n\n          -  Patients who have a history of breast cancer and/or who have received prior\n             chemotherapy, endocrine therapy, or radiation therapy\n\n          -  Patients who have breast implants\n\n          -  Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque\n             lesions)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Eligible patients are all patients, who are scheduled for a standard core biopsy of lung,\n        liver or breast; or percutaneous RFA of liver in the Netherlands Cancer Institute\n        (NKI-AvL), Amsterdam, The Netherlands. In the enrollment process the \"patient informatie\"\n        will be used and the informed consent must be signed prior to the intervention."
            }
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730365", 
            "org_study_id": "NL40578.031.12"
        }, 
        "intervention": {
            "arm_group_label": "Histological biopsy procedures", 
            "description": "Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.", 
            "intervention_name": "Core biopsy procedure", 
            "intervention_type": "Procedure", 
            "other_name": [
                "Histological biopsy procedure", 
                "Standard biopsy procedure"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "spectroscopy", 
            "tumour", 
            "biopsy", 
            "malignancy"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "j.spliethoff@nki.nl", 
                "last_name": "Jarich Spliethoff, MSc", 
                "phone": "+31 020 5127491"
            }, 
            "facility": {
                "address": {
                    "city": "Amsterdam", 
                    "country": "Netherlands", 
                    "state": "Noord-Holland", 
                    "zip": "1066 CX"
                }, 
                "name": "Nederlands Kanker Instituut/Antonie van Leeuwenhoek Ziekenhuis"
            }, 
            "investigator": [
                {
                    "last_name": "Warner Prevoo, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jarich Spliethoff, MSc", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_groups": "1", 
        "official_title": "Discrimination of Benign and Malignant Human Tissue During Percutaneous Interventions Using Optical Spectroscopy Techniques", 
        "overall_contact": {
            "email": "t.ruers@nki.nl", 
            "last_name": "Theo Ruers, MD", 
            "phone": "+31 020 5152565"
        }, 
        "overall_contact_backup": {
            "email": "j.spliethoff@nki.nl", 
            "last_name": "Jarich Spliethoff, MSc", 
            "phone": "+31 020 5127491"
        }, 
        "overall_official": {
            "affiliation": "Nederlands Kanker Instituut/Antonie van leeuwenhoek Ziekenhuis", 
            "last_name": "Theo Ruers, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Medical Ethics Review Committee (METC)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Statistical analysis of the difference between diffuse reflectance spectra obtained at normal and malignant measurement locations", 
            "measure": "Differentiation between normal and malignant tissue", 
            "safety_issue": "No", 
            "time_frame": "Day 0"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730365"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Philips Healthcare", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Philips Healthcare", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}